Skip to Main content Skip to Navigation
Journal articles

Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data

Abstract : Aims: Intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy is standard care for neovascular age-related macular degeneration (nAMD), but the recommended monthly injection regimen is burdensome. Evidence suggests low injection/monitoring frequencies in clinical practice and suboptimal vision outcomes. This observational cohort study uses administrative claims data from the French national healthcare system to assess anti-VEGF treatment patterns and nAMD-specific healthcare resource demands and costs. Patients and methods: nAMD patients ≥50 years initiating intravitreal ranibizumab, aflibercept or bevacizumab treatment (2014‒2015), and propensity score-matched non-nAMD patients (controls), were identified from the Echantillon Généraliste de Bénéficiaires database. Outcomes of interest included anti-VEGF treatment patterns, and healthcare resource utilization and associated costs of patients vis-à-vis controls over 24 months. Results: Study patients (n = 355) received (mean) 5.2 and 2.4 anti-VEGF injections over 0‒12 and 12‒24 months, respectively. Most patients (79.0%) remained on their initial anti-VEGF agent; among treatment switchers the most common transition was from ranibizumab to aflibercept. During follow-up, nAMD patients were more likely than controls to require ophthalmology visits (99.7% vs 44.8%), ocular procedures (optical coherence tomography/angiography/fundoscopy) (96.9% vs 27.2%), cataract surgery (13.0% vs 6.7%), and medical transports (38.0% vs 31.9%). Mean numbers of ophthalmology visits (25.1 vs 1.2) and medical transports (6.0 vs 3.5) were higher (p<.01) among nAMD patients. Total reimbursed costs were two-fold higher for nAMD patients than controls (mean €16,799 vs €8255) due to higher treatment costs (€6847 vs €1156), medical fees (€1858 vs €295), hospital fees (€6396 vs €5235), and transport costs (€358 vs €259). Excess total healthcare cost was (mean) €5279 and €7918 over the first 12 and 24 months of treatment, respectively. Conclusions: Current intravitreal anti-VEGF treatment and monitoring requirements place considerable economic burden on the French healthcare system. New intravitreal therapies with extended dosing intervals and predictable efficacy might reduce demand on ophthalmology services.
Document type :
Journal articles
Complete list of metadata
Contributor : Sabine Julien <>
Submitted on : Wednesday, August 25, 2021 - 10:23:32 AM
Last modification on : Saturday, August 28, 2021 - 12:31:25 PM

Links full text




Jean-François Korobelnik, Cécile Delcourt, Catherine Creuzot-Garcher, Asma Melaine, Jules Chassetuillier, et al.. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data. Journal of Medical Economics, Taylor & Francis, In press, pp.1-37. ⟨10.1080/13696998.2021.1971416⟩. ⟨hal-03325648⟩



Record views